Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun:209:115322.
doi: 10.1016/j.addr.2024.115322. Epub 2024 Apr 26.

Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design

Jennifer Stevenson  1 , Rachel Poker  2 , Johanna Schoss  3 , Michael Campbell  4 , Claire Everitt  5 , Brian Holly  5 , Nicholas Stones  6 , Ronald J Pettis  7 , Manuel Sanchez-Felix  8
Affiliations
Review

Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design

Jennifer Stevenson et al. Adv Drug Deliv Rev. 2024 Jun.

Abstract

Subcutaneous (SC) drug delivery can be a safe, effective alternative to the traditional intravenous route of administration, potentially offering notable advantages for both patients and healthcare providers. The SC Drug Development & Delivery Consortium convened in 2018 to raise awareness of industry challenges to advance the development of patient-centric SC drug delivery strategies. The SC Consortium identified better understanding of patient preferences and perspectives as necessary to optimize SC product design attributes and help guide design decisions during SC product development. This manuscript provides a comprehensive overview of patient-centric factors for consideration in the SC drug delivery design and development process with the aim of establishing a foundation of existing knowledge for patient experiences related to SC drug delivery. This overview is informed by the outcomes of a multi-step survey of Consortium members and key pharmaceutical stakeholders. Framed in the context of the patient's treatment journey, the survey findings offer future perspectives to fill data gaps to advance patient-centric SC drug delivery.

Keywords: Patient experience; Patient preferences; Patient-centric drug delivery; Subcutaneous injection device design attributes; Subcutaneous injection devices; Treatment adherence; Treatment initiation; Treatment selection.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Jennifer Stevenson is an employee and stockholder of Amgen. Rachel Poker was an employee and stockholder of AstraZeneca at the time of manuscript development. Johanna Schoss is an employee and stockholder of Biogen. Michael Campbell is an employee and stockholder of Janssen. Claire Everitt and Brian Holly are employees and stockholders of Pfizer. Nicholas Stones is an employee and stockholder of Novartis Pharma AG. Ronald J. Pettis is an employee and stockholder of Becton-Dickinson. Manuel Sanchez-Felix is an employee of Halozyme and stockholder of Halozyme and Novartis.

LinkOut - more resources